Moderna (MRNA) has been struggling to shake one label for years: Covid winner.
That label helped to make the company famous, but it also became a problem for the stock when pandemic demand dropped and investors questioned whether Moderna could develop a stable business beyond one historic product cycle.
Now the corporation may have a fresh response.
The Food and Drug Administration (FDA) is getting ready to evaluate Moderna’s messenger RNA-based flu shot, MFLUSIVA, Fierce Biotech reported, and the landscape appears more positive than investors might have expected. The problem is larger than a single seasonal vaccine.
For Moderna investors, the question is whether the company’s mRNA platform can be a recurring commercial engine or just another pandemic-era success tale.
Moderna CEO Stéphane Bancel said the company is “excited to return to sales growth in 2026.”
Moderna needs proof that its vaccine platform still matters
The bull case for Moderna has always been a straightforward promise: mRNA can be utilized to make medicines and vaccines faster than existing platforms.
That promise worked magnificently during the Covid pandemic.
But investors in public companies don’t reward scientific potential indefinitely. What they want is repeatable revenue, lucrative launches, and proof that a platform can deliver more than one blockbuster cycle.
And that’s when the tale for Moderna’s stock got messy.
Covid vaccine sales plummeted from pandemic highs, losses increased, and investors began to see the company as a show-me story. Moderna had $389 million in revenue in the first quarter, up from the preceding year, but it still lost $1.3 billion net. Cash, cash equivalents, and investments were $7.5 billion compared to $8.1 billion at the end of 2025.
That financial backdrop is even more important in today’s market.
The Federal Reserve kept rates unchanged on June 17, Reuters noted, but officials indicated that a rate move could happen later in 2026 if inflation stays above target. Higher rate expectations can make investors less patient with non-profitable growth firms, notably biotech names that rely on pipeline execution.
Related: Moderna gets good news as it searches for life after Covid
This is why MFLUSIVA is important.
A Covid boom would not be a seasonal flu vaccination. But it could be a way for investors to see that Moderna can convert its mRNA technology into a regular source of vaccine revenue in a huge, mature market.
That would shift the discussion from whether Moderna got lucky during Covid to whether it still has a platform that Wall Street should appreciate.
FDA’s flu-shot review may shift the Moderna debate
The FDA’s Vaccines and Related Biological Products Advisory Committee is set to meet June 18 to discuss the safety and effectiveness of MFLUSIVA for the prevention of influenza in individuals 50 years and older. The FDA says it usually adopts advisory committee recommendations, although they’re not binding.
That meeting comes after a tortuous regulatory journey.
Moderna’s flu shot application was criticized earlier this year for its trial design, The Detroit News reported. The worry was whether the study had used the correct control condition (a standard-dose flu shot) for those aged 65 and older, since older adults are commonly advised to receive enhanced flu shots.
More Health Care:
- Mark Cuban floats controversial way to cut health costs
- Medicare and health insurance company files Chapter 11 bankruptcy
- Microsoft and Copilot just hit a jackpot in healthcare
The new setup looks more positive.
Data suggesting an immunological response to MFLUSIVA could support efficacy in persons 65 and older, FDA personnel told Reuters. The shot also showed better relative vaccination efficacy than a standard-dose flu vaccine in adults ages 50 to 64, according to the briefing documents seen by Reuters.
But that does not eliminate the risk.
FDA staff also pointed to limitations such as that the vaccine was evaluated during only one flu season, and that immunocompromised people and very weak older adults were excluded from trials. Moderna has promised to conduct another trial and submit more data among people 65 years and older if cleared for that age group.
Still, the message for the investor is plain.
Moderna is asking for traditional approval for adults aged 50 to 64 and accelerated approval for adults aged 65 and above. If authorized, MFLUSIVA would be the first mRNA-based seasonal flu vaccine in the U.S., with a decision by the FDA expected by Aug. 5.
That was the reason for the quick response of Moderna shares. They were trading near $61, up more than 10% on June 17, valuing the company at about $24.2 billion.
Bloomberg / Getty Images
What Moderna investors should watch next
The first thing investors should look at is the advisory committee vote.
A yes vote wouldn’t mean it’s a done deal, but it would put greater emphasis on Moderna’s decision date in August for the stock. It would also provide a cleaner mechanism for investors to underwrite the company’s respiratory vaccination strategy.
The second problem is the label.
Approval in adults 50 to 64 would be useful. But the older-adult demographic is more commercially important, since flu risk increases with age, and that market currently supports higher-value vaccine choices.
That’s why the FDA’s perspective on those 65 and older might be the most essential aspect of the narrative.
The final question: Can Moderna translate acceptance into uptake?
The flu vaccine market is not a desert. Moderna would be up against established businesses with existing ties, significant manufacturing size, and a lengthy history with public health purchasers. A regulatory success would just be step one, not the end of the road.
The fourth problem is combination vaccinations.
Moderna’s wider respiratory approach includes Covid, flu, respiratory syncytial virus, and combo vaccinations. A genuine flu vaccine might be a boon to that portfolio because it gives Moderna another annual vaccination touchpoint.
That is the unseen upside. Investors are not just watching one FDA meeting. They’re watching to see if Moderna can establish a respiratory franchise that brings its mRNA technology back into commercial relevance.
What to remember about Moderna stock
- Moderna’s flu-shot review matters because it tests the company’s post-Covid platform story, Fierce Biotech notes.
- FDA staff comments appear more constructive than earlier regulatory pushback.
- The June 18 advisory committee vote is the next major catalyst.
- Older-adult approval would carry greater commercial significance than a narrower label.
- Moderna still faces launch, competition, and follow-up study risks.
- A flu approval could strengthen the case for Moderna’s broader respiratory vaccine strategy.
Ultimately, Moderna’s FDA moment is about more than MFLUSIVA. Investors want to know whether the corporation is a durable vaccine platform company.
A positive FDA result will not fix all the problems. Moderna is still unprofitable, squandering cash, and fighting in a challenging vaccination market.
But it would give investors something they’ve been waiting for: confirmation that the company’s mRNA platform can generate yet another major commercial product.
This could help shift the stock story from Covid recovery to platform credibility.
Related: Eli Lilly sends strong message on vaccine strategy
